Annual report pursuant to Section 13 and 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.21.1
Note 3 - Revenue From Contracts With Customers (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   
Years Ended
December 31,
 
   
2020
   
2019
 
Royalty revenue:
               
Tc99m tilmanocept - Europe
  $
7,995
    $
16,665
 
                 
License revenue:
               
Tc99m tilmanocept - Europe
  $
110,730
    $
 
NAV4694
   
     
9,953
 
Total license revenue
  $
110,730
    $
9,953
 
                 
Other revenue:
               
Additional stability studies
  $
    $
11,024
 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   
Year Ended December 31,
 
   
2020
   
2019
 
Total deferred revenue, beginning of period
  $
700,000
    $
711,024
 
Revenue deferred related to sublicense
   
160,000
     
495,000
 
Refund of deferred revenue related to sublicense
   
(160,000
)
   
(495,000
)
Revenue recognized from satisfaction of performance obligations
   
     
(11,024
)
Total deferred revenue, end of period
  $
700,000
    $
700,000